As summer heat turns to cool winds, hopes that this year would bring widespread industry relief have dissipated, with ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

Ten years after first collecting an FDA approval, it’s time for version number two. | Cologuard Plus represents the next ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...

Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a ...

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the ...

The digital pathology developer Proscia is launching an artificial intelligence toolkit for life science researchers, ...

One of those companies, a contract research organization focused on genetic medicines called Franklin Biolabs, officially ...

Septerna is about to find out how a biotech without “any meaningful clinical data” fares in the late 2024 IPO market. | ...

Legend Biotech appears to be on a mission to shake up its cell therapy development. | A week after signing up to collaborate ...